'This Isn't The Past Novartis,' Jimenez Tells JPM Conference
This article was originally published in Scrip
Executive Summary
Novartis AG is making faster decisions. That's the message CEO Joseph Jimenez wanted investors at the JP Morgan Healthcare conference Jan. 11 to take away. He vowed the company would not spend years investing to turn around its Alcon eye care business before making a decision about considering alternative options for the unit.
You may also be interested in...
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.
INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage
Novartis Oncology President Bruno Strigini talks about refining the pharma major's oncology strategy and its pipeline potential.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.